Robbins Farley’s Genmab GMAB Stock Holding History

Robbins Farley’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250	Closed	-$10K	–	182
2020 Q4	$10K	Buy	+250	New	+$9.35K	0.01%	73

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Robbins Farley's GMAB Position: Q1 2021 in Review

Robbins Farley sold out of Genmab (GMAB) in Q1 2021, closing a stake of 250 shares — an estimated $10K sold.

Robbins Farley first reported a position in GMAB in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 209 funds tracked by Wall St. Rank hold GMAB as of Q1 2021.

Robbins Farley reported no remaining Genmab position as of Q1 2021 after selling out during the quarter.
Robbins Farley sold 250 Genmab shares in Q1 2021, an estimated $10K.
Robbins Farley first reported a position in Genmab in Q4 2020 and held it in 1 quarter.
Robbins Farley's Genmab position peaked at $10K in Q4 2020.
209 funds tracked by Wall St. Rank held Genmab as of Q1 2021.

Based on Robbins Farley's 13F filing for Q1 2021, filed 13 May 2021.